GrayBug LLC is conducting preclinical work on its microparticle anti-VEGF compound GB-102, an extended-release injectable for wet AMD. The platform encapsulates the active drug ingredient in microparticles that degrade over time once injected into the eye to gradually release the agent. In mouse studies, GB-102 has been shown to prolong suppression of choroidal neovascularization 4.5 times longer than ranibizumab alone, President and CEO Michael O’Rourke said, potentially extending the interval between anti-VEGF injections from every one to two months to every four to six months. The company is also doing early work in glaucoma and other areas as well, O’Rourke said.
Michael has 20 years of global ophthalmic leadership experience across pharmaceuticals, drug delivery and medical devices.